DanielleElyseAntin-OzerkisMD
Pulmonology • North Haven, CTCritical Care Medicine
Associate Professor, Internal Medicine, Yale University School of Medicine
Dr. Antin-Ozerkis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6 Devine Street
Yale New Haven Health North Haven Medical Center
North Haven, CT 06473
Education & Training
University of Pennsylvania Health SystemFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2006- University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Perelman School of Medicine at the University of PennsylvaniaClass of 1999
Certifications & Licensure
CT State Medical License 2006 - 2025
PA State Medical License 2000 - 2006- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Start of enrollment: 2009 Oct 01
- AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Start of enrollment: 2009 Oct 01
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
- Join now to see all
Publications & Presentations
PubMed
- 234 citationsPrognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.Sunil Singhal, Anil Vachani, Danielle Antin-Ozerkis, Larry R. Kaiser, Steven M. Albelda
Clinical Cancer Research. 2005-06-01 - 194 citationsMacitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trialGanesh Raghu, Rachel Million-Rousseau, Adele Morganti, Loïc Perchenet, Juergen Behr
The European Respiratory Journal. 2013-12-01 - 175 citationsCirculating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.Susan K. Mathai, Mridu Gulati, Xueyan Peng, Thomas Russell, Albert C. Shaw
Laboratory Investigation; a Journal of Technical Methods and Pathology. 2010-06-01
Press Mentions
2023 ‘Top Doctors’ List Features Over 250 Yale Medicine PhysiciansMay 3rd, 2023- Following Computational Predictions, Scientists Demonstrate That Cancer Drug Counters Pulmonary FibrosisSeptember 1st, 2022
- Saracatinib as Effective, or Superior to Ofev, Esbriet in IPF Models: StudyAugust 30th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
